CAS 282089-49-0
:N-(1,3-benzodioxol-5-ylméthyl)-1,2-dihydro-7-méthoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide
- JTE 907
- 3-Quinolinecarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-
- N-(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide
- N-(Benzo[d][1,3]dioxol-5-ylMethyl)-7-Methoxy-2-oxo-8-(pentyloxy)-1,2-dihydro-quinolin-3-carboxaMide
- JTE907
- N-(benzo[d][1,3]dioxol-5-ylMethyl)-7-Methoxy-2-oxo-8-(pentyl
- N-(benzo[d][1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-(pentyloxy)-1,2-dihydroquinoline-3-carboxamide
JTE-907
CAS :JTE-907 是一种具有高度选择性和口服活性的 CB2 受体反向激动剂。JTE-907在体内展现出抗炎活性。Formule :C24H26N2O6Degré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :438.47Ref: TM-T19705
1mg52,00€5mg119,00€10mg177,00€25mg313,00€50mg465,00€100mg662,00€1mL*10mM (DMSO)142,00€JTE-907
CAS :Produit contrôléJTE-907 is a cannabinoid drug that binds to the CB2 receptor and has been shown to have anti-inflammatory properties in animal models of inflammatory bowel disease. It also has a high affinity for the CB2 receptor, which is expressed in immune cells, and low affinity for the CB1 receptor. JTE-907 has been shown to decrease levels of pro-inflammatory cytokines and increase levels of anti-inflammatory cytokines. The drug also increases angiogenic factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which are important for blood vessel formation. In addition, JTE-907 has been shown to inhibit neuronal activity in vitro and show beneficial effects on biological properties in animals with autoimmune diseases.
Degré de pureté :Min. 95%



